INFLUENCE OF AN ANTI-ANGIOGENIC TREATMENT ON 9L GLIOSARCOMA - OXYGENATION AND RESPONSE TO CYTOTOXIC THERAPY

被引:96
作者
TEICHER, BA [1 ]
HOLDEN, SA [1 ]
ARA, G [1 ]
DUPUIS, NP [1 ]
LIU, F [1 ]
YUAN, J [1 ]
IKEBE, M [1 ]
KAKEJI, Y [1 ]
机构
[1] JOINT CTR RADIAT THERAPY,BOSTON,MA 02115
关键词
D O I
10.1002/ijc.2910610523
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tissue oxygen tensions were measured in subcutaneously growing rat 9L gliosarcoma under normal air and carbogen breathing conditions prior to and after i.v. administration of a perflubron emulsion. When these animals were treated with the anti-angiogenic agents TNP-470 and minocycline for 5 days prior to oxygen measurement, tumor hypoxia was decreased compared with untreated tumors. Hypoxia, defined as the percent of pO(2) readings less than or equal to 5 mm Hg, was decreased from 71% in untreated air-breathing controls to 34% in animals treated with the anti-angiogenic agents, the perflubron emulsion and carbogen breathing. These effects were manifest in the increased response of the tumor to single-dose (10, 20 and 30 Gy) radiation therapy. Twenty-four hours after treatment with BCNU oxygenation of the tumors was not altered; however, 24 hr after administration of adriamycin oxygenation of the tumors was increased such that hypoxia in adriamycin-treated tumors in animals receiving the perflubron emulsion and carbogen was reduced to 21%. Tumor growth delay in the s.c. tumors was increased by the addition of treatment with the anti-angiogenic agents from day 4 through day 18 post-tumor cell implantation along with BCNU or adriamycin on days 7-11. Administration of the perflubron emulsion and carbogen breathing resulted in increased tumor growth delay with the chemotherapeutic agents alone and in combination with the anti-angiogenic agents. Life span in animals bearing intracranially implanted 9L gliosarcoma progressively increased with administration of the anti-angiogenic agents and then the anti-angiogenic agents and perflubron emulsion/carbogen compared to treatment with BCNU or adriamycin. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:732 / 737
页数:6
相关论文
共 38 条
[31]  
TEICHER BA, 1994, IN PRESS RAD ONCOL I
[32]  
TOI M, 1993, INT J ONCOL, V3, P525
[33]  
VAUPEL P, 1991, CANCER RES, V51, P3316
[34]  
Vaupel Peter W., 1993, P53
[35]  
YAMAMOTO T, 1994, ANTICANCER RES, V14, P1
[36]  
YAMAOKA M, 1993, CANCER RES, V53, P4262
[37]  
YAMAOKA M, 1993, CANCER RES, V53, P5233
[38]  
YANASE T, 1993, J PHARMACOL EXP THER, V264, P469